# Deucravacitinib (Bristol Myers Squibb)
Who / What
Deucravacitinib is a **tyrosine kinase 2 (TYK2) inhibitor** developed as an oral medication for the treatment of moderate-to-severe plaque psoriasis. It targets specific pathways in the immune system to reduce inflammation, offering a novel therapeutic approach beyond traditional biologic treatments.
Background & History
Deucravacitinib was developed by **Bristol Myers Squibb (BMS)**, a pharmaceutical company specializing in oncology and immunology. The compound emerged from research into targeted kinase inhibitors, designed to address autoimmune diseases like psoriasis. Key milestones include preclinical studies validating its mechanism of action and subsequent clinical trials demonstrating efficacy and safety.
Why Notable
Deucravacitinib stands out due to its **novel TYK2 inhibition**, offering a potential alternative for patients with limited treatment options or resistance to other biologics. Its approval for plaque psoriasis marks a significant advancement in managing chronic autoimmune conditions, improving quality of life by reducing symptoms like skin plaques and itching.
In the News
As of recent years, deucravacitinib has gained attention for its **potential role in expanding treatment options** for psoriasis, particularly among patients who do not respond well to other therapies. Ongoing clinical data and regulatory discussions continue to highlight its relevance in dermatology and immunology research.
